PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1)
enzyme, approved for treatment of IDH1-mutant (m IDH1) acute myeloid leukemia (AML) …

The changes associated with malignancy are not only in cancer cells but also in
environment in which cancer cells live. Metabolic reprogramming supports tumor cell high …

Somatic point mutations at a key arginine residue (R132) within the active site of the
metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in …

The grading of gliomas based on histological features has been a subject of debate for
several decades. A consensus has not yet been reached because of technical limitations …

Hypermethylation of the promoters of tumour suppressor genes represses transcription of
these genes, conferring growth advantages to cancer cells. How these changes arise is …

The acquisition of cancer hallmarks requires molecular alterations at multiple levels
including genome, epigenome, transcriptome, proteome, and metabolome. In the past …

Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2 …

The regulation of oxidative stress is an important factor in both tumour development and
responses to anticancer therapies. Many signalling pathways that are linked to …

In contrast to terminally differentiated cells, cancer cells and stem cells retain the ability to re-
enter the cell cycle and proliferate. To proliferate, cells must increase their uptake and …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …